Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
Jing Zhang, Yan Gu, Baoan Chen Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People’s Republic of ChinaCorrespondence: Baoan Chen, Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People’s...
Main Authors: | Zhang J, Gu Y, Chen B |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-02-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/drug-resistance-mechanism-and-new-targeted-drugs-and-treatments-of-rel-peer-reviewed-fulltext-article-CMAR |
Similar Items
-
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01) -
Promising therapeutic approaches for relapsed/refractory multiple myeloma
by: Beiwen Ni, et al.
Published: (2022-12-01) -
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
by: Jain MD, et al.
Published: (2018-05-01) -
Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
by: Anna Nydegger, et al.
Published: (2021-12-01) -
Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
by: Yurkiewicz IR, et al.
Published: (2018-07-01)